Analytical Data
-
Gene name
Hemojuvelin
-
简介
The Hemojuvelin protein is a membrane-bound and soluble protein in mammals, also known as rejection directing Molecule C (RGMc) or hemochromatosis type 2 protein (HFE2). Hemojuvelin works by inhibiting the MAPK-JNK pathway that inhibits the growth, adhesion, migration, and invasion of prostate cancer cells. Hemojuvelin Protein, Cynomolgus (sf9, His) is the recombinant cynomolgus-derived Hemojuvelin protein, expressed by Sf9 insect cells , with C-His labeled tag.
- Application
-
Alternative Names
hemochromatosis type 2 (juvenile)
-
Species
Cynomolgus
-
Source
Baculovirus
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
EHH15137
-
Expression Region
Q36-S400
-
Protein Length
Partial
-
Molecular Weight
32 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Hemojuvelin is a key protein involved in the regulation of iron homeostasis and erythropoiesis, and it has gained significant attention due to its role in iron overload disorders such as hereditary hemochromatosis. The discovery of hemojuvelin in the early 2000s highlighted its importance as a modulator of hepcidin, the master regulator of iron metabolism, which is produced by the liver in response to cellular iron levels. Mutations or dysregulation of hemojuvelin can lead to disorders characterized by excessive iron accumulation, resulting in severe complications affecting the liver, heart, and endocrine organs. Research into recombinant hemojuvelin has sought to elucidate its structure-function relationship and its potential therapeutic applications. This includes exploring its role in diseases like anemia of chronic disease and other conditions tied to iron dysregulation. By producing and characterizing recombinant hemojuvelin, scientists aim to provide insights into its mechanisms of action and pave the way for innovative treatments targeting iron metabolism, ultimately improving patient outcomes in iron-related disorders.
